Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications.

Volkow ND, Fowler JS, Wang GJ, Shumay E, Telang F, Thanos PK, Alexoff D.

PLoS One. 2010 Dec 7;5(12):e15269. doi: 10.1371/journal.pone.0015269.

2.

Fast uptake and long-lasting binding of methamphetamine in the human brain: comparison with cocaine.

Fowler JS, Volkow ND, Logan J, Alexoff D, Telang F, Wang GJ, Wong C, Ma Y, Kriplani A, Pradhan K, Schlyer D, Jayne M, Hubbard B, Carter P, Warner D, King P, Shea C, Xu Y, Muench L, Apelskog K.

Neuroimage. 2008 Dec;43(4):756-63. doi: 10.1016/j.neuroimage.2008.07.020. Epub 2008 Jul 22.

3.

PET studies of d-methamphetamine pharmacokinetics in primates: comparison with l-methamphetamine and ( --)-cocaine.

Fowler JS, Kroll C, Ferrieri R, Alexoff D, Logan J, Dewey SL, Schiffer W, Schlyer D, Carter P, King P, Shea C, Xu Y, Muench L, Benveniste H, Vaska P, Volkow ND.

J Nucl Med. 2007 Oct;48(10):1724-32. Epub 2007 Sep 14.

4.

Human pharmacology of the methamphetamine stereoisomers.

Mendelson J, Uemura N, Harris D, Nath RP, Fernandez E, Jacob P 3rd, Everhart ET, Jones RT.

Clin Pharmacol Ther. 2006 Oct;80(4):403-20.

PMID:
17015058
5.

Methamphetamine and the expanding complications of amphetamines.

Albertson TE, Derlet RW, Van Hoozen BE.

West J Med. 1999 Apr;170(4):214-9. Review.

6.

Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats.

Milesi-Hallé A, Hendrickson HP, Laurenzana EM, Gentry WB, Owens SM.

Toxicol Appl Pharmacol. 2005 Dec 15;209(3):203-13.

PMID:
15916788
7.

Methamphetamine blood concentrations in human abusers: application to pharmacokinetic modeling.

Melega WP, Cho AK, Harvey D, Laćan G.

Synapse. 2007 Apr;61(4):216-20.

PMID:
17230548
8.

Comparison of intranasal methamphetamine and d-amphetamine self-administration by humans.

Kirkpatrick MG, Gunderson EW, Johanson CE, Levin FR, Foltin RW, Hart CL.

Addiction. 2012 Apr;107(4):783-91. doi: 10.1111/j.1360-0443.2011.03706.x.

9.

Approaches to the development of medications for the treatment of methamphetamine dependence.

Vocci FJ, Appel NM.

Addiction. 2007 Apr;102 Suppl 1:96-106. Review.

PMID:
17493058
10.

Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat.

Rivière GJ, Byrnes KA, Gentry WB, Owens SM.

J Pharmacol Exp Ther. 1999 Dec;291(3):1220-6.

11.

Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats.

Byrnes-Blake KA, Laurenzana EM, Carroll FI, Abraham P, Gentry WB, Landes RD, Owens SM.

Eur J Pharmacol. 2003 Feb 14;461(2-3):119-28.

PMID:
12586207
12.

The effect of d-methamphetamine on simulated driving performance.

Silber BY, Croft RJ, Downey LA, Papafotiou K, Camfield DA, Stough C.

Hum Psychopharmacol. 2012 Mar;27(2):139-44. doi: 10.1002/hup.1238.

PMID:
22389077
13.

Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers.

Schepers RJ, Oyler JM, Joseph RE Jr, Cone EJ, Moolchan ET, Huestis MA.

Clin Chem. 2003 Jan;49(1):121-32.

14.

The bioavailability of intranasal and smoked methamphetamine.

Harris DS, Boxenbaum H, Everhart ET, Sequeira G, Mendelson JE, Jones RT.

Clin Pharmacol Ther. 2003 Nov;74(5):475-86.

PMID:
14586388
15.

Drug interaction between methamphetamine and antihistamines: behavioral changes and tissue concentrations of methamphetamine in rats.

Okuda T, Ito Y, Nakagawa N, Hishinuma T, Tsukamoto H, Iwabuchi K, Watanabe T, Kitaichi K, Goto J, Yanai K.

Eur J Pharmacol. 2004 Nov 28;505(1-3):135-44.

PMID:
15556146
16.

Polymorphisms in CYP2D6 may predict methamphetamine related heart failure.

Sutter ME, Gaedigk A, Albertson TE, Southard J, Owen KP, Mills LD, Diercks DB.

Clin Toxicol (Phila). 2013 Aug;51(7):540-4. doi: 10.3109/15563650.2013.818684. Epub 2013 Jul 15.

PMID:
23855716
17.

Distribution and kinetics of carbon-11-cocaine in the human body measured with PET.

Volkow ND, Fowler JS, Wolf AP, Wang GJ, Logan J, MacGregor R, Dewey SL, Schlyer D, Hitzemann R.

J Nucl Med. 1992 Apr;33(4):521-5.

18.

Could sigma receptor ligands be a treatment for methamphetamine addiction?

Rodvelt KR, Miller DK.

Curr Drug Abuse Rev. 2010 Sep;3(3):156-62. Review.

PMID:
21054260
19.

Isradipine, a dihydropyridine-class calcium channel antagonist, attenuates some of d-methamphetamine's positive subjective effects: a preliminary study.

Johnson BA, Roache JD, Bordnick PS, Ait-Daoud N.

Psychopharmacology (Berl). 1999 Jun;144(3):295-300.

PMID:
10435398
20.

Increased plasma concentration and brain penetration of methamphetamine in behaviorally sensitized rats.

Kitaichi K, Morishita Y, Doi Y, Ueyama J, Matsushima M, Zhao YL, Takagi K, Hasegawa T.

Eur J Pharmacol. 2003 Mar 7;464(1):39-48.

PMID:
12600693

Supplemental Content

Support Center